May 2014 | Oncology & Biotech News

Frontline Treatment Questions Abound as Generic Imatinib Approaches

June 10, 2014

The frontline treatment of patients with Philadelphia chromosome–positive (Ph+) chronic myelogenous leukemia (CML) continues to be debated as imatinib (Gleevec) rapidly approaches the end of its patent protection and next-generation agents continue to show efficacy in clinical trials.

2014 NCCN Guideline Updates: Experts Highlight New Recommendations for Clinical Practice

June 06, 2014

At the recent National Comprehensive Cancer Network (NCCN) 19th Annual Conference, experts discussed this year's updates to the NCCN Clinical Practice Guidelines in Oncology. The meeting also included reviews of NCCN Task Force reports on issues in supportive care. We asked eleven NCCN panel members to select the most significant updates and insights presented at the conference.